Investigational drug · Phase 3
SPG601
Also called: Codabakalner
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD), Fragile X Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "SPG601"
First trial start
2024
Jul 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPG601", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fragile X Syndrome (FXS)
- Autism Spectrum Disorder (ASD)
- Fragile X Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SPG601" as an intervention, largest first.
- A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADSPivotal-lookingNot yet recruiting
SpinogenixIndustry
NCT07439510 · 120 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 1, 2030
Drug: Codabakalner; Placebo · For: Fragile X Syndrome (FXS); Autism Spectrum Disorder (ASD)
SpinogenixIndustry
NCT06413537 · 10 participants · Start Jul 5, 2024 · Primary completion Dec 31, 2024
Drug: SPG601; Placebo · For: Fragile X Syndrome
Sites: Cincinnati, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- SPG601-associated modulation of resting-state EEG and improvement in executive function in a fragile X syndrome randomized controlled crossover study.
Pedapati EV, Vanderklish PW, Sarraf ST, et al. · Sci Rep 2026
Also in development for Fragile X Syndrome (FXS)
- cannabidiol as a clear that can be applied to the skinZYN002, transdermal deliveryPhase 31 trial
Harmony Biosciences Management, Inc. · Fragile X Syndrome, Fragile X Syndrome (FXS)
- CTH120Phase 21 trial
Connecta Therapeutics, S.L. · Fragile X Syndrome (FXS), Fragile X Syndrome
- S247240Phase 21 trial
Institut de Recherches Internationales Servier (I.R.I.S.) · Fragile X Syndrome (FXS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.